About Ligand Pharmaceuticals
Ligand Pharmaceuticals is a company based in San Diego (United States) founded in 1987. The company has 68 employees as of December 31, 2024. Ligand Pharmaceuticals has completed 16 acquisitions, including Ab Initio, Apeiron Biologics and Crystal Biosciences. Ligand Pharmaceuticals offers products and services including Captisol Technology and Royalty Portfolio Management.
- Headquarter San Diego, United States
- Employees 68 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ligand Pharmaceuticals Incorporated
-
Annual Revenue
$167.13 M (USD)27.28as on Dec 31, 2024
-
Net Profit
-$4.03 M (USD)-107.73as on Dec 31, 2024
-
EBITDA
$60.41 M (USD)27.89as on Dec 31, 2024
-
Latest Funding Round
$650 M (USD), Post-IPO
May 18, 2018
-
Investors
Not available
-
Employee Count
68
as on Dec 31, 2024
-
Investments & Acquisitions
Ab Initio
& 15 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Ligand Pharmaceuticals
Ligand Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol LGND in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Ligand Pharmaceuticals
Ligand Pharmaceuticals offers a comprehensive portfolio of products and services, including Captisol Technology and Royalty Portfolio Management.
This technology is utilized for enhancing drug solubility and stability in development processes
Royalties from biopharmaceutical programs are managed across various disease areas
People of Ligand Pharmaceuticals
Unlock access to complete
Unlock access to complete
Funding Insights of Ligand Pharmaceuticals
Investments & Acquisitions by Ligand Pharmaceuticals
Ligand Pharmaceuticals has strategically engaged in corporate development activities, having acquired 16 companies. Notable acquisitions include Ab Initio, Apeiron Biologics and Crystal Biosciences.
Investment portfolio details for Ligand Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Novel cow antibodies are developed for therapeutic applications.
|
Locked | Locked | 2018 | Locked | |
|
Developer of immuno-oncology antibody therapeutics
|
Locked | Locked | 2016 | Locked | |
|
GPCR-modulating protein agents and immuno-oncology drugs are developed.
|
Locked | Locked | 2015 | Locked |
Complete acquisition details for Ligand Pharmaceuticals
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Ligand Pharmaceuticals
Detailed financials for Ligand Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ligand Pharmaceuticals Comparisons
Peer comparison for Ligand Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ligand Pharmaceuticals
Detailed competitors of Ligand Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ligand Pharmaceuticals
Complete news archive for Ligand Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ligand Pharmaceuticals
Ligand Pharmaceuticals was founded in 1987 and raised its 1st funding round 27 years after it was founded.
Ligand Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Todd Davis is the current CEO of Ligand Pharmaceuticals.
As of Dec 31, 2024, the latest employee count at Ligand Pharmaceuticals is 68.
Annual revenue of Ligand Pharmaceuticals is $167.13M as on Dec 31, 2024.
Ligand Pharmaceuticals was founded in 1987 and is headquartered in San Diego, United States. Operations are centered on the biopharmaceutical sector, where drugs are developed, manufactured, and commercialized for therapeutic applications. The company is led by CEO Todd Davis. Focus is placed on innovative pharmaceutical solutions, with activities conducted primarily in the domestic market. Domain services support ongoing research and production efforts.
Ligand Pharmaceuticals offers Captisol Technology and Royalty Portfolio Management.
Yes, Ligand Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol LGND.
Ligand Pharmaceuticals has made 16 acquisitions, including Ab Initio, Apeiron Biologics, and Crystal Biosciences.
The ticker symbol of Ligand Pharmaceuticals is LGND on NASDAQ.